These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21602934)

  • 1. Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.
    Rudick RA; Rani MR; Xu Y; Lee JC; Na J; Shrock J; Josyula A; Fisher E; Ransohoff RM
    PLoS One; 2011; 6(5):e19262. PubMed ID: 21602934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis.
    Satoh J; Nanri Y; Tabunoki H; Yamamura T
    BMC Neurol; 2006 May; 6():18. PubMed ID: 16709257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.
    Koike F; Satoh J; Miyake S; Yamamoto T; Kawai M; Kikuchi S; Nomura K; Yokoyama K; Ota K; Kanda T; Fukazawa T; Yamamura T
    J Neuroimmunol; 2003 Jun; 139(1-2):109-18. PubMed ID: 12799028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon -beta therapy in multiple sclerosis].
    Satoh J
    Nihon Rinsho; 2006 Jul; 64(7):1297-309. PubMed ID: 16838648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta.
    Rani MR; Xu Y; Lee JC; Shrock J; Josyula A; Schlaak J; Chakraborthy S; Ja N; Ransohoff RM; Rudick RA
    Ann N Y Acad Sci; 2009 Dec; 1182():58-68. PubMed ID: 20074275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.
    de Jong TD; Vosslamber S; Mantel E; de Ridder S; Wesseling JG; van der Pouw Kraan TC; Leurs C; Hegen H; Deisenhammer F; Killestein J; Lundberg IE; Vencovsky J; Nurmohamed MT; van Schaardenburg D; Bultink IE; Voskuyl AE; Pegtel DM; van der Laken CJ; Bijlsma JW; Verweij CL
    Arthritis Res Ther; 2016 Feb; 18():49. PubMed ID: 26882897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
    van Baarsen LG; Vosslamber S; Tijssen M; Baggen JM; van der Voort LF; Killestein J; van der Pouw Kraan TC; Polman CH; Verweij CL
    PLoS One; 2008 Apr; 3(4):e1927. PubMed ID: 18382694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.
    Serana F; Imberti L; Amato MP; Comi G; Gasperini C; Ghezzi A; Martinelli V; Provinciali L; Rottoli MR; Sotgiu S; Stecchi S; Vecchio M; Zaffaroni M; Cordioli C; Capra R
    PLoS One; 2014; 9(4):e94794. PubMed ID: 24733382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis.
    Xavier A; Campagna MP; Maltby VE; Kilpatrick T; Taylor BV; Butzkueven H; Ponsonby AL; Scott RJ; Jokubaitis VG; Lea RA; Lechner-Scott J
    Front Immunol; 2023; 14():1162796. PubMed ID: 37325639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.
    Goodin DS
    Drugs; 2001; 61(12):1693-703. PubMed ID: 11693459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
    Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
    Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients.
    Satoh J; Nakanishi M; Koike F; Onoue H; Aranami T; Yamamoto T; Kawai M; Kikuchi S; Nomura K; Yokoyama K; Ota K; Saito T; Ohta M; Miyake S; Kanda T; Fukazawa T; Yamamura T
    J Neuroimmunol; 2006 May; 174(1-2):108-18. PubMed ID: 16564577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.
    Vosslamber S; van der Voort LF; van den Elskamp IJ; Heijmans R; Aubin C; Uitdehaag BM; Crusius JB; van der Pouw Kraan TC; Comabella M; Montalban X; Hafler DA; De Jager PL; Killestein J; Polman CH; Verweij CL
    Genes Immun; 2011 Sep; 12(6):466-72. PubMed ID: 21471993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.